Department of Medicine and Therapeutics, Division of Neurology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Int J Stroke. 2011 Aug;6(4):312-4. doi: 10.1111/j.1747-4949.2011.00634.x.
The recruitment of the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis, an National Institute of Neurological Disorders and Stroke-funded clinic trial evaluating aggressive medical therapy vs. adjunctive intracranial angioplasty and stenting in high-grade symptomatic intracranial stenosis, was prematurely terminated by the study Data Safety Monitoring Board. The significantly higher 30-day stroke and death rate in the stenting arm led to a conclusion from the National Institute of Neurological Disorders and Stroke and the Executive Committee that aggressive medical management alone was superior to angioplasty combined with stenting. The authors discussed on the potential pitfalls, which may render this conclusion premature and explained the needs for continuing efforts in investigating treatment for intracranial stenosis.
血管内支架成形术和强化药物治疗预防颅内狭窄患者卒中复发的临床试验，该试验由美国国立神经病学与卒中研究院资助，旨在评估强化药物治疗与颅内血管成形术和支架置入术联合治疗重度症状性颅内狭窄的疗效。由于支架治疗组 30 天内卒中发生率和死亡率显著升高，美国国立神经病学与卒中研究院和执行委员会得出结论，强化药物治疗单独应用优于血管成形术联合支架置入术。本文作者讨论了导致这一结论可能不成熟的潜在陷阱，并解释了继续努力研究颅内狭窄治疗方法的必要性。
